Thursday - March 26, 2026

EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the EGFR + NSCLC … Continue reading

Metastatic Pancreatic Cancer Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Metastatic Pancreatic Cancer Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the Metastatic Pancreatic Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It … Continue reading

JAK Inhibitor Therapeutic Pipeline Strengthens as 50+ Pharma Companies Advance Over 55 Drug Candidates | DelveInsight

JAK Inhibitor Pipeline JAK Inhibitor companies include Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, and Arcutis Biotherapeutics/Reistone Biopharma, among others. The global therapeutic landscape for Janus kinase (JAK) inhibitors … Continue reading

Architecture of Sales Emerges as the Go-To Sales Partner for Foreign SaaS Companies Entering the Polish Market

The Gdańsk-based sales agency has successfully guided companies from Estonia, the Netherlands, and beyond into Poland’s fast-growing B2B market — delivering qualified meetings, first paying clients, and sustainable pipeline growth. Architecture of Sales (AoS), a Polish B2B sales and market … Continue reading